Olema Pharmaceuticals, Inc. (OLMA)
7.58
+0.22
(+2.99%)
USD |
NASDAQ |
Nov 10, 10:21
Olema Pharmaceuticals Enterprise Value : 186.24M for Nov. 9, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 09, 2026 | 186.24M |
| November 06, 2026 | 183.61M |
| November 05, 2026 | 133.77M |
| November 04, 2026 | 201.98M |
| November 03, 2026 | 185.36M |
| November 02, 2026 | 160.88M |
| October 30, 2026 | 154.76M |
| October 29, 2026 | 183.61M |
| October 28, 2026 | 197.61M |
| October 27, 2026 | 158.25M |
| October 26, 2026 | 121.52M |
| October 23, 2026 | 103.16M |
| October 22, 2026 | 156.50M |
| October 21, 2026 | 159.13M |
| October 20, 2026 | 176.62M |
| October 19, 2026 | 164.38M |
| October 16, 2026 | 118.03M |
| October 15, 2026 | 143.39M |
| October 14, 2026 | 137.26M |
| October 13, 2026 | 156.50M |
| October 12, 2026 | 186.24M |
| October 09, 2026 | 226.47M |
| October 08, 2026 | 226.47M |
| October 07, 2026 | 236.96M |
| October 06, 2026 | 235.21M |
| Date | Value |
|---|---|
| October 05, 2026 | 264.07M |
| October 02, 2026 | 261.88M |
| October 01, 2026 | 265.82M |
| September 30, 2026 | 298.18M |
| September 29, 2026 | 289.43M |
| September 28, 2026 | 295.55M |
| September 25, 2026 | 307.80M |
| September 24, 2026 | 333.16M |
| September 23, 2026 | 314.79M |
| September 22, 2026 | 385.63M |
| September 21, 2026 | 384.75M |
| September 18, 2026 | 401.37M |
| September 17, 2026 | 408.37M |
| September 16, 2026 | 393.50M |
| September 15, 2026 | 397.87M |
| September 14, 2026 | 442.47M |
| September 11, 2026 | 436.35M |
| September 10, 2026 | 477.45M |
| September 09, 2026 | 448.59M |
| September 08, 2026 | 503.25M |
| September 04, 2026 | 482.70M |
| September 03, 2026 | 480.95M |
| September 02, 2026 | 489.70M |
| September 01, 2026 | 466.09M |
| August 31, 2026 | 454.72M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Puma Biotechnology, Inc. | 339.92M |
| SELLAS Life Sciences Group, Inc. | 1.595B |
| ACADIA Pharmaceuticals, Inc. | 1.946B |
| Alnylam Pharmaceuticals, Inc. | 20.38B |
| Anika Therapeutics, Inc. | 176.34M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -63.20M |
| Total Expenses (Quarterly) | 63.20M |
| EPS Diluted (Quarterly) | -0.605 |
| Earnings Yield | -27.94% |
| Normalized Earnings Yield | -27.95 |